Gilead Sciences, Inc. (NASDAQ:GILD) Stake Reduced by Selkirk Management LLC

Selkirk Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 52.9% during the first quarter, Holdings Channel reports. The institutional investor owned 40,000 shares of the biopharmaceutical company’s stock after selling 45,000 shares during the period. Gilead Sciences accounts for 1.4% of Selkirk Management LLC’s holdings, making the stock its 19th largest position. Selkirk Management LLC’s holdings in Gilead Sciences were worth $2,717,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Hall Laurie J Trustee increased its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC increased its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. 74.02% of the stock is owned by institutional investors.

Gilead Sciences, Inc. (GILD) traded up 0.449% on Monday, hitting $72.725. 1,002,340 shares of the stock traded hands. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10. The company’s 50 day moving average price is $72.36 and its 200-day moving average price is $68.77. The stock has a market capitalization of $94.97 billion, a P/E ratio of 7.899 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period last year, the company posted $3.08 EPS. Analysts predict that Gilead Sciences, Inc. will post $8.76 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is 22.58%.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/08/14/gilead-sciences-inc-nasdaqgild-stake-reduced-by-selkirk-management-llc.html.

A number of research firms have recently issued reports on GILD. Jefferies Group LLC restated a “hold” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 11th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research report on Tuesday, April 25th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $76.00 price objective (up from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Twelve investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $80.31.

In related news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock worth $15,223,184 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply